ArriVent BioPharma Inc. C...

NASDAQ: AVBP · Real-Time Price · USD
22.84
0.03 (0.13%)
At close: Jun 27, 2025, 3:59 PM
22.91
0.33%
After-hours: Jun 27, 2025, 05:54 PM EDT

Company Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors.

The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002.

It has strategic collaborations with Aarvik Therapeutics Inc.

The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ArriVent BioPharma Inc. Common Stock
ArriVent BioPharma Inc. Common Stock logo
Country United States
IPO Date Jan 26, 2024
Industry Biotechnology
Sector Healthcare
Employees 52
CEO Zhengbin Yao

Contact Details

Address:
18 Campus Boulevard
Newtown Square,
United States
Website https://www.arrivent.com

Stock Details

Ticker Symbol AVBP
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001868279
CUSIP Number 04272N102
ISIN Number US04272N1028
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Zhengbin Yao Ph.D. Co-Founder, Chairman, President & Chief Executive Officer
Robin LaChapelle M.A. Co-Founder & Chief Operating Officer
Winston Kung M.B.A. Chief Financial Officer & Treasurer
Yang Wang Ph.D. Chief Technology Officer
Dr. James Paul Kastenmayer J.D., Ph.D. General Counsel & Secretary
Dr. Stuart Lutzker M.D., Ph.D. Co-Founder, President of Research & Development and Director
Meghna Chowdary Senior Vice President of Commercial Strategy

Latest SEC Filings

Date Type Title
Jun 23, 2025 8-K Current Report
Jun 20, 2025 4 Filing
Jun 20, 2025 4 Filing
Jun 20, 2025 4 Filing
Jun 20, 2025 4 Filing
Jun 20, 2025 8-K Current Report
May 15, 2025 SCHEDULE 13G Filing
May 12, 2025 10-Q Quarterly Report
May 12, 2025 8-K Current Report
Apr 29, 2025 4 Filing